View in EDS

Efficacy and safety of dupilumab in pediatric patients aged 6 months to 11 years with erythrodermic atopic dermatitis: A post-hoc analysis of 3 clinical trials.

Saved in:
Bibliographic Details
Title: Efficacy and safety of dupilumab in pediatric patients aged 6 months to 11 years with erythrodermic atopic dermatitis: A post-hoc analysis of 3 clinical trials.
Authors: Paller AS; Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois; Ann and Robert H. Lurie Children's Hospital, Chicago, Illinois. Electronic address: APaller@nm.org., Siegfried EC; Department of Pediatrics, Saint Louis University, St. Louis, Missouri; Cardinal Glennon Children's Hospital, St. Louis, Missouri., Cork MJ; Department of Infection, Immunity and Cardiovascular Disease, Sheffield Dermatology Research, University of Sheffield, Sheffield, United Kingdom; Children's Hospital, Sheffield, United Kingdom., Kabashima K; Department of Dermatology, Kyoto University Graduate School of Medicine, Kyoto, Japan., Arkwright PD; Lydia Becker Institute of Immunology & Inflammation, University of Manchester, Manchester, United Kingdom., Gębska E; DERMAPOLIS Medical Dermatology Center, Chorzów, Poland., Chen Z; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Zahn J; Regeneron Pharmaceuticals Inc, Tarrytown, New York., Rossi AB; Sanofi, Cambridge, Massachusetts.
Source: Journal of the American Academy of Dermatology [J Am Acad Dermatol] 2025 Oct; Vol. 93 (4), pp. 1066-1070. Date of Electronic Publication: 2025 May 27.
Publication Type: Journal Article
Journal Info: Publisher: Mosby Country of Publication: United States NLM ID: 7907132 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-6787 (Electronic) Linking ISSN: 01909622 NLM ISO Abbreviation: J Am Acad Dermatol Subsets: MEDLINE; In Process
Database: MEDLINE Ultimate
Description
ISSN:1097-6787
DOI:10.1016/j.jaad.2025.05.1422